Alfredo Fusco

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8775899/publications.pdf

Version: 2024-02-01

345	21,746	8172	14197
papers	citations	76 h-index	128 g-index

359	359	359	19227
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5399-5404.	1.8	950
2	PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell, 1990, 60, 557-563.	13.5	905
3	Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nature Medicine, 2002, 8, 1136-1144.	15.2	644
4	Roles of HMGA proteins in cancer. Nature Reviews Cancer, 2007, 7, 899-910.	12.8	627
5	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research, 2002, 62, 7284-90.	0.4	463
6	Regulation of Thyroid Cell Proliferation by TSH and Other Factors: A Critical Evaluation of in Vitro Models. Endocrine Reviews, 2001, 22, 631-656.	8.9	412
7	MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocrine-Related Cancer, 2007, 14, 791-798.	1.6	383
8	Increased BDNF Promoter Methylation in the Wernicke Area of Suicide Subjects. Archives of General Psychiatry, 2010, 67, 258.	13.8	336
9	Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer. Cancer Research, 2005, 65, 10199-10207.	0.4	319
10	The RET receptor: function in development and dysfunction in congenital malformation. Trends in Genetics, 2001, 17, 580-589.	2.9	268
11	Expression of theRET/PTCFusion Gene as a Marker for Papillary Carcinoma in Hashimoto's Thyroiditis. Laryngoscope, 1997, 107, 95-100.	1.1	243
12	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 2005, 115, 1068-1081.	3.9	231
13	Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene, 2004, 23, 6056-6063.	2.6	227
14	HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell, 2006, 9, 459-471.	7.7	226
15	Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Letters, 2004, 574, 1-8.	1.3	206
16	Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nature Medicine, 2005, 11, 765-773.	15.2	204
17	Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene, 2002, 21, 3190-3198.	2.6	201
18	Aurora B Overexpression Associates with the Thyroid Carcinoma Undifferentiated Phenotype and Is Required for Thyroid Carcinoma Cell Proliferation. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 928-935.	1.8	184

#	Article	IF	Citations
19	RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. European Journal of Endocrinology, 2006, 155, 645-653.	1.9	176
20	RET/Papillary Thyroid Cancer Rearrangement in Nonneoplastic Thyrocytes: Follicular Cells of Hashimotoâ€™s Thyroiditis Share Low-Level Recombination Events with a Subset of Papillary Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2414-2423.	1.8	175
21	DNA Damage, Homology-Directed Repair, and DNA Methylation. PLoS Genetics, 2007, 3, e110.	1.5	170
22	A Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma. Cancer Research, 2007, 67, 10148-10158.	0.4	167
23	Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFÎºB p65 protein expression. Oncogene, 1997, 15, 1987-1994.	2.6	165
24	Minireview: RET: Normal and Abnormal Functions. Endocrinology, 2004, 145, 5448-5451.	1.4	160
25	RET/PTC Activation in Hyalinizing Trabecular Tumors of the Thyroid. American Journal of Surgical Pathology, 2000, 24, 1615-1621.	2.1	152
26	PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1. Oncogene, 2000, 19, 3146-3155.	2.6	139
27	Assessment of RET/PTC Oncogene Activation and Clonality in Thyroid Nodules with Incomplete Morphological Evidence of Papillary Carcinoma. American Journal of Pathology, 2002, 160, 2157-2167.	1.9	139
28	Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene, 2005, 24, 3427-3435.	2.6	137
29	Molecular Mechanisms of RET Activation in Human Cancer. Annals of the New York Academy of Sciences, 2002, 963, 116-121.	1.8	137
30	Altered MicroRNA Expression Profile in Human Pituitary GH Adenomas: Down-Regulation of miRNA Targeting HMGA1, HMGA2, and E2F1. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1128-E1138.	1.8	136
31	CBX7 is a tumor suppressor in mice and humans. Journal of Clinical Investigation, 2012, 122, 612-623.	3.9	133
32	HMGA and Cancer. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2010, 1799, 48-54.	0.9	132
33	Analysis of the HMGI nuclear proteins in mouse neoplastic cells induced by different procedures. Experimental Cell Research, 1989, 184, 538-545.	1.2	126
34	Inhibitory Effects of Peroxisome Proliferator-Activated Receptor Î³ on Thyroid Carcinoma Cell Growth. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4728-4735.	1.8	126
35	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 2005, 115, 1068-1081.	3.9	126
36	Negative Regulation of BRCA1 Gene Expression by HMGA1 Proteins Accounts for the Reduced BRCA1 Protein Levels in Sporadic Breast Carcinoma. Molecular and Cellular Biology, 2003, 23, 2225-2238.	1.1	119

#	Article	IF	Citations
37	Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene, 2004, 23, 5958-5967.	2.6	119
38	Familial Cancer Associated with a Polymorphism inARLTS1. New England Journal of Medicine, 2005, 352, 1667-1676.	13.9	119
39	Understanding p27kip1Deregulation in Cancer: Downregulation or Mislocalizaiton?. Cell Cycle, 2002, 1, 394-400.	1.3	117
40	Efficient Inhibition of RET/Papillary Thyroid Carcinoma Oncogenic Kinases by 4-Amino-5-(4-Chloro-Phenyl)-7-(t-Butyl)Pyrazolo[3,4-d]Pyrimidine (PP2). Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1897-1902.	1.8	115
41	Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene, 1998, 17, 413-418.	2.6	113
42	Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret. Oncogene, 1998, 16, 2435-2445.	2.6	112
43	Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. Oncogene, 2005, 24, 1882-1894.	2.6	111
44	Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. Journal of Clinical Investigation, 1999, 104, 865-874.	3.9	110
45	Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer, 1994, 73, 2206-2212.	2.0	109
46	HMGA Proteins Up-regulate CCNB2 Gene in Mouse and Human Pituitary Adenomas. Cancer Research, 2009, 69, 1844-1850.	0.4	107
47	High Mobility Group A Proteins as Tumor Markers. Frontiers in Medicine, 2015, 2, 15.	1.2	107
48	Loss of the CBX7 Gene Expression Correlates with a Highly Malignant Phenotype in Thyroid Cancer. Cancer Research, 2008, 68, 6770-6778.	0.4	106
49	Down-Regulation of the miR-25 and miR-30d Contributes to the Development of Anaplastic Thyroid Carcinoma Targeting the Polycomb Protein EZH2. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E710-E718.	1.8	105
50	Haploinsufficiency of the Hmga1 Gene Causes Cardiac Hypertrophy and Myelo-Lymphoproliferative Disorders in Mice. Cancer Research, 2006, 66, 2536-2543.	0.4	104
51	MiR-1 Is a Tumor Suppressor in Thyroid Carcinogenesis Targeting CCND2, CXCR4, and SDF-1Î±. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1388-E1398.	1.8	104
52	Regulation of Thyroid Cell Proliferation by TSH and Other Factors: A Critical Evaluation of in Vitro Models. , 2001, 22, 631-656.		104
53	Potent Mitogenicity of the RET/PTC3 Oncogene Correlates with Its Prevalence in Tall-Cell Variant of Papillary Thyroid Carcinoma. American Journal of Pathology, 2002, 160, 247-254.	1.9	103
54	Deregulation of microRNA expression in thyroid neoplasias. Nature Reviews Endocrinology, 2014, 10, 88-101.	4.3	103

#	Article	IF	Citations
55	The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Research, 2002, 62, 1077-82.	0.4	101
56	The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene, 2000, 19, 5729-5735.	2.6	100
57	Rat Protein Tyrosine Phosphatase Î· Suppresses the Neoplastic Phenotype of Retrovirally Transformed Thyroid Cells through the Stabilization of p27 Kip1. Molecular and Cellular Biology, 2000, 20, 9236-9246.	1.1	99
58	RET Activation and Clinicopathologic Features in Poorly Differentiated Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 370-379.	1.8	99
59	HMGA1 and HMGA2 protein expression in mouse spermatogenesis. Oncogene, 2002, 21, 3644-3650.	2.6	98
60	Dual effect on the RET receptor of MENâ€‰2 mutations affecting specific extracytoplasmic cysteines. Oncogene, 1998, 17, 2851-2861.	2.6	97
61	Phosphorylation of High-Mobility Group Protein A2 by Nek2 Kinase during the First Meiotic Division in Mouse Spermatocytes. Molecular Biology of the Cell, 2004, 15, 1224-1232.	0.9	97
62	Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene, 1997, 15, 2687-2698.	2.6	96
63	Complex Regulation of the Cyclin-Dependent Kinase Inhibitor p27kip1 in Thyroid Cancer Cells by the PI3K/AKT Pathway. American Journal of Pathology, 2005, 166, 737-749.	1.9	96
64	TheRET/PTCOncogene Is Frequently Activated in Oncocytic Thyroid Tumors (Hurthle Cell) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 Endocrinology and Metabolism, 2002, 87, 364-369.	1.8	93
65	Deregulation of microRNA expression in follicular cell-derived human thyroid carcinomas. Endocrine-Related Cancer, 2010, 17, F91-F104.	1.6	90
66	High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. Journal of Clinical Investigation, 2007, 117, 693-702.	3.9	88
67	Molecular profile of hyalinizing trabecular tumours of the thyroid: High prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations. European Journal of Cancer, 2005, 41, 816-821.	1.3	87
68	Functional Variants of the <emph type="ital">HMGA1</emph> Gene and Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2011, 305, 903.	3.8	87
69	High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene, 2001, 20, 6132-6141.	2.6	86
70	Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation. Molecular and Cellular Biology, 2001, 21, 2485-2495.	1.1	86
71	A Novel Member of the BTB/POZ Family, PATZ, Associates with the RNF4 RING Finger Protein and Acts as a Transcriptional Repressor. Journal of Biological Chemistry, 2000, 275, 7894-7901.	1.6	83
72	Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. European Journal of Cancer, 2010, 46, 1438-1444.	1.3	83

#	Article	IF	Citations
73	The ret/ptc1 Oncogene Is Activated in Familial Adenomatous Polyposis-Associated Thyroid Papillary Carcinomas1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1003-1006.	1.8	82
74	Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene, 2002, 21, 2971-2980.	2.6	82
75	The Î²-Catenin Axis Integrates Multiple Signals Downstream from RET/Papillary Thyroid Carcinoma Leading to Cell Proliferation. Cancer Research, 2009, 69, 1867-1876.	0.4	82
76	HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology, 2012, 60, 397-404.	1.6	82
77	High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. International Journal of Cancer, 2001, 91, 147-151.	2.3	82
78	HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. Genes Chromosomes and Cancer, 1998, 23, 279-285.	1.5	78
79	Oncogenic Alterations in Papillary Thyroid Cancers of Young Patients. Thyroid, 2012, 22, 17-26.	2.4	78
80	miR-23b and miR-130b expression is downregulated in pituitary adenomas. Molecular and Cellular Endocrinology, 2014, 390, 1-7.	1.6	78
81	The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. European Journal of Cancer, 2010, 46, 2304-2313.	1.3	76
82	Genetic Alterations in Thyroid Carcinoma Associated with Familial Adenomatous Polyposis: Clinical Implications and Suggestions for Early Detection. World Journal of Surgery, 1998, 22, 1231-1236.	0.8	75
83	HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis, 2003, 24, 1191-1198.	1.3	75
84	A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocrine-Related Cancer, 2013, 20, 809-823.	1.6	74
85	Conditional Expression of RET/PTC Induces a Weak Oncogenic Drive in Thyroid PCCL3 Cells and Inhibits Thyrotropin Action at Multiple Levels. Molecular Endocrinology, 2003, 17, 1425-1436.	3.7	73
86	Chromobox Protein Homologue 7 Protein, with Decreased Expression in Human Carcinomas, Positively Regulates E-Cadherin Expression by Interacting with the Histone Deacetylase 2 Protein. Cancer Research, 2009, 69, 7079-7087.	0.4	72
87	HMGA1pseudogenes as candidate proto-oncogenic competitive endogenous RNAs. Oncotarget, 2014, 5, 8341-8354.	0.8	72
88	The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis. Oncogene, 2004, 23, 8432-8438.	2.6	71
89	RPSAP52 lncRNA is overexpressed in pituitary tumors and promotes cell proliferation by acting as miRNA sponge for HMGA proteins. Journal of Molecular Medicine, 2019, 97, 1019-1032.	1.7	71
90	Somatostatin Inhibits PC Cl3 Thyroid Cell Proliferation through the Modulation of Phosphotyrosine Phosphatase Activity. Journal of Biological Chemistry, 1996, 271, 6129-6136.	1.6	70

#	Article	IF	Citations
91	Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. International Journal of Cancer, 1995, 64, 171-175.	2.3	69
92	HMGA1 Protein Overexpression in Human Breast Carcinomas. Clinical Cancer Research, 2004, 10, 7637-7644.	3.2	69
93	Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein. Genes and Cancer, 2010, 1, 210-224.	0.6	69
94	The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas. Cancer Research, 2002, 62, 2398-405.	0.4	69
95	TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. Nucleic Acids Research, 2006, 34, 364-372.	6.5	67
96	TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. European Journal of Cancer, 2011, 47, 926-933.	1.3	66
97	HMGA1 silencing restores normal stem cell characteristics in colon cancer stem cells by increasing p53 levels. Oncotarget, 2014, 5, 3234-3245.	0.8	65
98	Loss of Hmga1 gene function affects embryonic stem cell lymphohematopoietic differentiation. FASEB Journal, 2003, 17, 1-27.	0.2	63
99	UbcH10 is overexpressed in malignant breast carcinomas. European Journal of Cancer, 2007, 43, 2729-2735.	1.3	62
100	Enhancer of Zeste Homolog 2 Overexpression Has a Role in the Development of Anaplastic Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1029-1038.	1.8	62
101	MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opinion on Therapeutic Targets, 2015, 19, 1017-1026.	1.5	62
102	HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. European Journal of Cancer, 2008, 44, 1015-1021.	1.3	61
103	Regulation of BRCA1 Transcription by Specific Single-Stranded DNA Binding Factors. Molecular and Cellular Biology, 2003, 23, 3774-3787.	1.1	58
104	HMGA2: A pituitary tumour subtype-specific oncogene?. Molecular and Cellular Endocrinology, 2010, 326, 19-24.	1.6	58
105	HIPK2 Controls Cytokinesis and Prevents Tetraploidization by Phosphorylating Histone H2B at the Midbody. Molecular Cell, 2012, 47, 87-98.	4.5	58
106	The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. Oncogene, 2001, 20, 209-218.	2.6	57
107	The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane. Oncogene, 2001, 20, 599-608.	2.6	57
108	miR-142â€“3p Down-Regulation Contributes to Thyroid Follicular Tumorigenesis by Targeting ASH1L and MLL1. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E59-E69.	1.8	57

#	Article	IF	Citations
109	Molecular defects in thyroid carcinomas: Role of the RET oncogene in thyroid neoplastic transformation. European Journal of Endocrinology, 1995, 133, 513-522.	1.9	56
110	Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells. Oncogene, 2003, 22, 1087-1097.	2.6	56
111	Akt-Dependent T198 Phosphorylation of Cyclin-Dependent Kinase Inhibitor p27^{kip1}in Breast Cancer. Cell Cycle, 2004, 3, 1072-1078.	1.3	56
112	Restoration of receptor-type protein tyrosine phosphatase Â function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. Carcinogenesis, 2004, 25, 2107-2114.	1.3	56
113	Reduced E-cadherin expression contributes to the loss of p27 kip1 -mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis, 2005, 26, 1021-1034.	1.3	56
114	miR-191 Down-Regulation Plays a Role in Thyroid Follicular Tumors through CDK6 Targeting. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1915-E1924.	1.8	56
115	Comparison of multiple forms of the high mobility group I proteins in rodent and human cells. Identification of the human high mobility group I-C protein. FEBS Journal, 1991, 198, 211-216.	0.2	55
116	The Expression of the Phosphotyrosine Phosphatase DEP-1/PTPÎ· Dictates the Responsivity of Glioma Cells to Somatostatin Inhibition of Cell Proliferation. Journal of Biological Chemistry, 2004, 279, 29004-29012.	1.6	55
117	Tyrosines 1015 and 1062 Arein VivoAutophosphorylation Sites in Ret and Ret-Derived Oncoproteins¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3898-3907.	1.8	54
118	High-Mobility Group A1 Proteins Regulate p53-Mediated Transcription of Bcl-2 Gene. Cancer Research, 2010, 70, 5379-5388.	0.4	54
119	Hmga1/Hmga2 double knock-out mice display a â€œsuperpygmyâ€•phenotype. Biology Open, 2014, 3, 372-378.	0.6	54
120	NCOA4 Transcriptional Coactivator Inhibits Activation of DNA Replication Origins. Molecular Cell, 2014, 55, 123-137.	4.5	54
121	siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Research, 2007, 36, e2-e2.	6.5	53
122	Thyroid Cell Transformation Inhibits the Expression of a Novel Rat Protein Tyrosine Phosphatase. Experimental Cell Research, 1997, 235, 62-70.	1.2	52
123	Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo. Oncogene, 1998, 17, 377-385.	2.6	51
124	Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene, 1999, 18, 4860-4869.	2.6	51
125	New somatic mutations andWNK1-B4GALNT3gene fusion in papillary thyroid carcinoma. Oncotarget, 2015, 6, 11242-11251.	0.8	51
126	ONYX-015, an E1B Gene-Defective Adenovirus, Induces Cell Death in Human Anaplastic Thyroid Carcinoma Cell Lines. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2525-2531.	1.8	50

#	Article	IF	Citations
127	RET/Papillary Thyroid Carcinoma Oncogenic Signaling through the Rap1 Small GTPase. Cancer Research, 2007, 67, 381-390.	0.4	50
128	Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription. EMBO Journal, 2007, 26, 1878-1890.	3.5	50
129	CDH16/Ksp-Cadherin Is Expressed in the Developing Thyroid Gland and Is Strongly Down-Regulated in Thyroid Carcinomas. Endocrinology, 2012, 153, 522-534.	1.4	50
130	RNF4 Is a Growth Inhibitor Expressed in Germ Cells but Not in Human Testicular Tumors. American Journal of Pathology, 2001, 159, 1225-1230.	1.9	49
131	The Activation of the Phosphotyrosine Phosphatase Î· (r-PTPÎ·) Is Responsible for the Somatostatin Inhibition of PC Cl3 Thyroid Cell Proliferation. Molecular Endocrinology, 2001, 15, 1838-1852.	3.7	49
132	An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. Cancer Research, 2003, 63, 882-6.	0.4	49
133	The rat tyrosine phosphatase Î· increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue. Oncogene, 2005, 24, 3187-3195.	2.6	48
134	HMGA1-pseudogene expression is induced in human pituitary tumors. Cell Cycle, 2015, 14, 1471-1475.	1.3	48
135	The Homeodomain-Interacting Protein Kinase 2 Gene Is Expressed Late in Embryogenesis and Preferentially in Retina, Muscle, and Neural Tissues. Biochemical and Biophysical Research Communications, 2002, 290, 942-947.	1.0	47
136	Activator Protein-2 Overexpression Accounts for Increased Insulin Receptor Expression in Human Breast Cancer. Cancer Research, 2006, 66, 5085-5093.	0.4	47
137	Genetic Ablation ofPtprj, a Mouse Cancer Susceptibility Gene, Results in Normal Growth and Development and Does Not Predispose to Spontaneous Tumorigenesis. DNA and Cell Biology, 2006, 25, 376-382.	0.9	47
138	The cAMP-HMGA1-RBP4 system: a novel biochemical pathway for modulating glucose homeostasis. BMC Biology, 2009, 7, 24.	1.7	47
139	Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. Oncogene, 2003, 22, 246-255.	2.6	46
140	Identification of the Genes Up- and Down-Regulated by the High Mobility Group A1 (HMGA1) Proteins. Cancer Research, 2004, 64, 5728-5735.	0.4	46
141	Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors. Cell Cycle, 2015, 14, 2590-2597.	1.3	46
142	RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho. Oncogene, 2001, 20, 6973-6982.	2.6	45
143	Regulation of p27Kip1 Protein Levels Contributes to Mitogenic Effects of the RET/PTC Kinase in Thyroid Carcinoma Cells. Cancer Research, 2004, 64, 3823-3829.	0.4	45
144	ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5027-5032.	1.8	44

#	Article	IF	Citations
145	The Receptor-Type Protein Tyrosine Phosphatase J Antagonizes the Biochemical and Biological Effects of RET-Derived Oncoproteins. Cancer Research, 2006, 66, 6280-6287.	0.4	44
146	Downâ€regulation of oestrogen receptorâ€Î² associates with transcriptional coâ€regulator PATZ1 delocalization in human testicular seminomas. Journal of Pathology, 2011, 224, 110-120.	2.1	44
147	PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration. Oncotarget, 2015, 6, 5310-5323.	0.8	44
148	Low frequency of p53 mutations in human thyroid tumors; p53 and Ras mutation in two out of fifty-six thyroid tumours. European Journal of Endocrinology, 1996, 134, 177-183.	1.9	43
149	Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation. Oncogene, 1999, 18, 6241-6251.	2.6	43
150	Translational regulation of a novel testis-specific RNF4 transcript. Molecular Reproduction and Development, 2003, 66, 1-7.	1.0	43
151	Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene, 2004, 23, 2188-2196.	2.6	43
152	FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Cancer, 2007, 7, 17.	1.1	43
153	The highâ€mobility group A1â€estrogen receptor Î² nuclear interaction is impaired in human testicular seminomas. Journal of Cellular Physiology, 2012, 227, 3749-3755.	2.0	43
154	Thyrotropin receptor gene expression in oncogene-transfected rat thyroid cells: Correlation between transformation, loss of thyrotropin-dependent growth, and loss of thyrotropin receptor gene expression. Biochemical and Biophysical Research Communications, 1990, 173, 172-178.	1.0	41
155	Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying theRET/PTC1 rearrangement. International Journal of Cancer, 2002, 97, 608-614.	2.3	41
156	The HMGA1-IGF-I/IGFBP System: A Novel Pathway for Modulating Glucose Uptake. Molecular Endocrinology, 2012, 26, 1578-1589.	3.7	41
157	HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models. Neoplasia, 2016, 18, 724-731.	2.3	41
158	Transformation of rat thyroid epithelial cells by kirsten murine sarcoma virus. International Journal of Cancer, 1981, 28, 655-662.	2.3	40
159	High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy. Endocrine-Related Cancer, 2005, 12, 867-874.	1.6	40
160	Critical Role of the HMGA2 Gene in Pituitary Adenomas. Cell Cycle, 2006, 5, 2045-2048.	1.3	40
161	Lovastatin Enhances the Replication of the Oncolytic Adenovirus dl1520 and Its Antineoplastic Activity against Anaplastic Thyroid Carcinoma Cells. Endocrinology, 2007, 148, 5186-5194.	1.4	40
162	Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas. Oncogene, 2001, 20, 885-892.	2.6	39

#	Article	IF	Citations
163	High-mobility group A1 proteins are overexpressed in human leukaemias. Biochemical Journal, 2003, 372, 145-150.	1.7	39
164	SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas. Clinical Cancer Research, 2007, 13, 2738-2744.	3.2	39
165	TWIST1 Plays a Pleiotropic Role in Determining the Anaplastic Thyroid Cancer Phenotype. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E772-E781.	1.8	39
166	High mobility group A1 protein modulates autophagy in cancer cells. Cell Death and Differentiation, 2017, 24, 1948-1962.	5.0	39
167	The Long Non-Coding RNA Prader Willi/Angelman Region RNA5 (PAR5) Is Downregulated in Anaplastic Thyroid Carcinomas Where It Acts as a Tumor Suppressor by Reducing EZH2 Activity. Cancers, 2020, 12, 235.	1.7	39
168	Cytokine Production by a New Undifferentiated Human Thyroid Carcinoma Cell Line, FB-11. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 4094-4100.	1.8	38
169	Mitogenic Effects of the Up-Regulation of Minichromosome Maintenance Proteins in Anaplastic Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4703-4709.	1.8	38
170	Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion. Endocrine-Related Cancer, 2010, 17, 989-999.	1.6	37
171	Epigenetic Mechanisms Leading to Overexpression of HMGA Proteins in Human Pituitary Adenomas. Frontiers in Medicine, 2015, 2, 39.	1.2	37
172	HMGA1-pseudogene overexpression contributes to cancer progression. Cell Cycle, 2014, 13, 3636-3639.	1.3	36
173	A polymorphism of HMGA1 protects against proliferative diabetic retinopathy by impairing HMGA1-induced VEGFA expression. Scientific Reports, 2016, 6, 39429.	1.6	36
174	UBE2C is overexpressed in ESCC tissues and its abrogation attenuates the malignant phenotype of ESCC cell lines. Oncotarget, 2016, 7, 65876-65887.	0.8	36
175	The Oncogenic Activity of RET Point Mutants for Follicular Thyroid Cells May Account for the Occurrence of Papillary Thyroid Carcinoma in Patients Affected by Familial Medullary Thyroid Carcinoma. American Journal of Pathology, 2004, 165, 511-521.	1.9	35
176	HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells. Expert Opinion on Therapeutic Targets, 2016, 20, 1169-1179.	1.5	35
177	HMGA1P7-pseudogene regulates H19 and Igf2 expression by a competitive endogenous RNA mechanism. Scientific Reports, 2016, 6, 37622.	1.6	35
178	Tyrosine Phosphatase PTPRJ/DEP-1 Is an Essential Promoter of Vascular Permeability, Angiogenesis, and Tumor Progression. Cancer Research, 2016, 76, 5080-5091.	0.4	35
179	UBE2C Is a Transcriptional Target of the Cell Cycle Regulator FOXM1. Genes, 2018, 9, 188.	1.0	35
180	PIT1 upregulation by HMGA proteins has a role in pituitary tumorigenesis. Endocrine-Related Cancer, 2012, 19, 123-135.	1.6	34

#	Article	IF	Citations
181	High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. BMC Cancer, 2014, 14, 851.	1.1	34
182	PATZ Attenuates the RNF4-mediated Enhancement of Androgen Receptor-dependent Transcription. Journal of Biological Chemistry, 2002, 277, 3280-3285.	1.6	33
183	The Phosphotyrosine Phosphatase Î· Mediates Somatostatin Inhibition of Glioma Proliferation via the Dephosphorylation of ERK1/2. Annals of the New York Academy of Sciences, 2004, 1030, 264-274.	1.8	33
184	Tumor Suppressor Role of theCL2/DRO1/CCDC80Gene in Thyroid Carcinogenesis. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2834-2843.	1.8	33
185	The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miRâ€603 and miRâ€10b expression. Molecular Oncology, 2013, 7, 531-542.	2.1	33
186	Deregulation of miR-183 and KIAA0101 in Aggressive and Malignant Pituitary Tumors. Frontiers in Medicine, 2015, 2, 54.	1.2	33
187	HMGA1-pseudogenes and cancer. Oncotarget, 2016, 7, 28724-28735.	0.8	33
188	Glial Cell Line-Derived Neurotrophic Factor Differentially Stimulates Ret Mutants Associated with the Multiple Endocrine Neoplasia Type 2 Syndromes and Hirschsprungâ€™s Disease1. Endocrinology, 1998, 139, 3613-3619.	1.4	32
189	UbcH10 expression in human lymphomas. Histopathology, 2009, 54, 731-740.	1.6	32
190	Isolation and Functional Characterization of Peptide Agonists of PTPRJ, a Tyrosine Phosphatase Receptor Endowed with Tumor Suppressor Activity. ACS Chemical Biology, 2012, 7, 1666-1676.	1.6	32
191	Loss of CCDC6, the First Identified RET Partner Gene, Affects pH2AX S139 Levels and Accelerates Mitotic Entry upon DNA Damage. PLoS ONE, 2012, 7, e36177.	1.1	32
192	High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer. Journal of Cellular Physiology, 2013, 229, n/a-n/a.	2.0	32
193	The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin. European Journal of Cancer, 2013, 49, 1142-1151.	1.3	31
194	Rat protein tyrosine phosphatase Î· physically interacts with the PDZ domains of syntenin. FEBS Letters, 2001, 500, 41-44.	1.3	30
195	HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity. Oncotarget, 2015, 6, 10320-10334.	0.8	30
196	HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. Oncogene, 2005, 24, 6809-6819.	2.6	29
197	Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. Endocrine-Related Cancer, 2007, 14, 405-420.	1.6	29
198	A TSH-CREB1-microRNA Loop Is Required for Thyroid Cell Growth. Molecular Endocrinology, 2011, 25, 1819-1830.	3.7	29

#	Article	IF	Citations
199	Tumor suppressor activity of CBX7 in lung carcinogenesis. Cell Cycle, 2012, 11, 1888-1891.	1.3	29
200	Thyrotropin Regulates Thyroid Cell Proliferation by Up-Regulating miR-23b and miR-29b that Target SMAD3. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3292-3301.	1.8	29
201	Embryonic defects and growth alteration in mice with homozygous disruption of the Patz1 gene. Journal of Cellular Physiology, 2013, 228, 646-653.	2.0	29
202	Identification and Characterization of a Novel RING-Finger Gene (RNF4) Mapping at 4p16.3. Genomics, 1998, 47, 258-265.	1.3	28
203	High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms. Journal of Gastroenterology, 2003, 38, 1144-1149.	2.3	28
204	A truncated HMGA1 gene induces proliferation of the 3T3-L1 pre-adipocytic cells: a model of human lipomas. Carcinogenesis, 2003, 24, 1861-1869.	1.3	28
205	Role of the high mobility group A proteins in the regulation of pituitary cell cycle. Journal of Molecular Endocrinology, 2010, 44, 309-318.	1.1	28
206	Discovery of PTPRJ Agonist Peptides That Effectively Inhibit in Vitro Cancer Cell Proliferation and Tube Formation. ACS Chemical Biology, 2013, 8, 1497-1506.	1.6	27
207	UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status. European Journal of Cancer, 2013, 49, 1117-1126.	1.3	27
208	CBX7 Modulates the Expression of Genes Critical for Cancer Progression. PLoS ONE, 2014, 9, e98295.	1.1	27
209	Deregulation of HMGA1 expression induces chromosome instability through regulation of spindle assembly checkpoint genes. Oncotarget, 2015, 6, 17342-17353.	0.8	27
210	HMGA2 overexpression plays a critical role in the progression of esophageal squamous carcinoma. Oncotarget, 2016, 7, 25872-25884.	0.8	27
211	20 years of RET/PTC in thyroid cancer: clinico-pathological correlations. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 731-735.	1.3	26
212	Aberrant expression, function and localization of connexins in human esophageal carcinoma cell lines with different degrees of tumorigenicity. Journal of Cancer Research and Clinical Oncology, 1994, 120, 445-453.	1.2	25
213	Diagnostic Significance of High Mobility Group I(Y) Protein Expression in Intraductal Papillary Mucinous Tumors of the Pancreas. Pancreas, 2002, 25, 198-204.	0.5	25
214	Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models. Cancer Gene Therapy, 2004, 11, 633-641.	2.2	25
215	Loss of p27 Expression Through RAS->BRAF->MAP Kinase-Dependent Pathway in Human Thyroid Carcinomas. Cell Cycle, 2007, 6, 2817-2825.	1.3	25
216	Role of PTPRJ genotype in papillary thyroid carcinoma risk. Endocrine-Related Cancer, 2010, 17, 1001-1006.	1.6	25

#	Article	IF	Citations
217	Let-7a Down-Regulation Plays a Role in Thyroid Neoplasias of Follicular Histotype Affecting Cell Adhesion and Migration through Its Ability to Target theFXYD5(Dysadherin) Gene. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E2168-E2178.	1.8	25
218	Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNAâ€328. FEBS Journal, 2013, 280, 401-412.	2.2	25
219	Hmga2 is necessary for Otx2-dependent exit of embryonic stem cells from the pluripotent ground state. BMC Biology, 2016, 14, 24.	1.7	25
220	Complementary actions of dopamine D2 receptor agonist and antiâ€vegf therapy on tumoral vessel normalization in a transgenic mouse model. International Journal of Cancer, 2017, 140, 2150-2161.	2.3	25
221	Polycomb protein family member CBX7 plays a critical role in cancer progression. American Journal of Cancer Research, 2015, 5, 1594-601.	1.4	25
222	The HMGA1 Pseudogene 7 Induces miR-483 and miR-675 Upregulation by Activating Egr1 through a ceRNA Mechanism. Genes, 2017, 8, 330.	1.0	24
223	HMGA1 negatively regulates NUMB expression at transcriptional and post transcriptional level in glioblastoma stem cells. Cell Cycle, 2019, 18, 1446-1457.	1.3	24
224	Cloning of the Rat Tissue Inhibitor of Metalloproteinases Type 2 (TIMP-2) Gene: Analysis of Its Expression in Normal and Transformed Thyroid Cells. Experimental Cell Research, 1994, 213, 398-403.	1.2	23
225	Critical role of cyclin D3 in TSH-dependent growth of thyrocytes and in hyperproliferative diseases of the thyroid gland. Oncogene, 2003, 22, 7576-7586.	2.6	23
226	Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy. Journal of Molecular Endocrinology, 2004, 33, 133-143.	1.1	23
227	E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression. Cell Division, 2006, 1, 17.	1.1	23
228	Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 1179-1186.	1.4	23
229	A ceRNA Circuitry Involving the Long Noncoding RNA Klhl14-AS, Pax8, and Bcl2 Drives Thyroid Carcinogenesis. Cancer Research, 2019, 79, 5746-5757.	0.4	23
230	HMGA1-Regulating microRNAs Let-7a and miR-26a are Downregulated in Human Seminomas. International Journal of Molecular Sciences, 2020, 21, 3014.	1.8	23
231	Status and expression of thep16INK4 gene in human thyroid tumors and thyroid-tumor cell lines. , 1996, 67, 29-34.		22
232	An Intracellular Multi-Effector Complex Mediates Somatostatin Receptor 1 Activation of Phospho-Tyrosine Phosphatase Î·. Molecular Endocrinology, 2007, 21, 229-246.	3.7	22
233	HMGA1 protein is a novel target of the ATM kinase. European Journal of Cancer, 2008, 44, 2668-2679.	1.3	22
234	CBX7 and HMGA1b proteins act in opposite way on the regulation of the SPP1 gene expression. Oncotarget, 2015, 6, 2680-2692.	0.8	22

#	Article	IF	Citations
235	miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene. BMC Cancer, 2017, 17, 170.	1.1	22
236	Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity. Oncotarget, 2015, 6, 15628-15638.	0.8	22
237	Derepression of HMGA2 Gene Expression in Retinoblastoma Is Associated with Cell Proliferation. Molecular Medicine, 2003, 9, 154-165.	1.9	21
238	UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients. Molecular Carcinogenesis, 2016, 55, 793-807.	1.3	21
239	HMGA and Cancer: A Review on Patent Literatures. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 258-267.	0.8	21
240	Targeted Disruption of the Murine Homeodomain-Interacting Protein Kinase-2 Causes Growth Deficiency In Vivo and Cell Cycle Arrest In Vitro. DNA and Cell Biology, 2009, 28, 161-167.	0.9	20
241	Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays. Scientific Reports, 2020, 10, 18850.	1.6	20
242	Oncogene Transformation of PC Cl3 Clonal Thyroid Cell Line Induces an Autonomous Pattern of Proliferation That Correlates with a Loss of Basal and Stimulated Phosphotyrosine Phosphatase Activity*. Endocrinology, 1997, 138, 3756-3763.	1.4	19
243	HMGA1 protein expression in familial breast carcinoma patients. European Journal of Cancer, 2010, 46, 332-339.	1.3	19
244	Mycalol: A Natural Lipid with Promising Cytotoxic Properties against Human Anaplastic Thyroid Carcinoma Cells. Angewandte Chemie - International Edition, 2013, 52, 9256-9260.	7.2	19
245	The R3 receptor-like protein tyrosine phosphatase subfamily inhibits insulin signalling by dephosphorylating the insulin receptor at specific sites. Journal of Biochemistry, 2015, 158, 235-243.	0.9	19
246	<scp>HMGA</scp>2, but not <scp>HMGA</scp>1, is overexpressed in human larynx carcinomas. Histopathology, 2018, 72, 1102-1114.	1.6	19
247	Overexpression of HMGA1 Figures as a Potential Prognostic Factor in Endometrioid Endometrial Carcinoma (EEC). Genes, 2019, 10, 372.	1.0	19
248	RPSAP52 lncRNA Inhibits p21Waf1/CIP Expression by Interacting With the RNA Binding Protein HuR. Oncology Research, 2020, 28, 191-201.	0.6	19
249	A new mechanism of BRAF activation in human thyroid papillary carcinomas. Journal of Clinical Investigation, 2005, 115, 20-23.	3.9	19
250	High mobility group A1 expression correlates with the histological grade of human glial tumors. Oncology Reports, 2004, 11, 1209-13.	1.2	19
251	A 12q13 Translocation Involving the HMGI-C Gene in Richter Transformation of a Chronic Lymphocytic Leukemia. Cancer Genetics and Cytogenetics, 2000, 119, 70-73.	1.0	18
252	UbcH10 expression on thyroid fineâ€needle aspirates. Cancer Cytopathology, 2010, 118, 157-165.	1.4	18

#	Article	IF	Citations
253	DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy. Oncology Letters, 2013, 6, 86-90.	0.8	18
254	Critical role of HMGA proteins in cancer cell chemoresistance. Journal of Molecular Medicine, 2017, 95, 353-360.	1.7	18
255	The complex CBX7-PRMT1 has a critical role in regulating E-cadherin gene expression and cell migration. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2019, 1862, 509-521.	0.9	18
256	The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells. Oncotarget, 2018, 9, 23334-23348.	0.8	18
257	CBX7 gene expression plays a negative role in adipocyte cell growth and differentiation. Biology Open, 2014, 3, 871-879.	0.6	17
258	High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. Molecular Carcinogenesis, 2017, 56, 2146-2157.	1.3	17
259	The Long Non-Coding RNA RP5-1024C24.1 and Its Associated-Gene MPPED2 Are Down-Regulated in Human Thyroid Neoplasias and Act as Tumour Suppressors. Cancers, 2018, 10, 146.	1.7	17
260	A new mechanism of BRAF activation in human thyroid papillary carcinomas. Journal of Clinical Investigation, 2005, 115, 20-23.	3.9	17
261	Protein Tyrosine Phosphatase-Î· Expression Is Upregulated by the PKA-Dependent and Is Downregulated by the PKC-Dependent Pathways in Thyroid Cells. Experimental Cell Research, 1998, 245, 195-202.	1.2	16
262	Sp1 and CTF/NF-1 Transcription Factors Are Involved in the Basal Expression of the Hmgi-c Proximal Promoter. Biochemical and Biophysical Research Communications, 1999, 265, 439-447.	1.0	16
263	Low-Resolution Structure and Fluorescence Anisotropy Analysis of Protein Tyrosine Phosphatase Î· Catalytic Domain. Biophysical Journal, 2007, 92, 4424-4432.	0.2	16
264	siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Research, 2008, 36, 6944-6944.	6.5	16
265	Interaction between HMGA1 and Retinoblastoma Protein Is Required for Adipocyte Differentiation. Journal of Biological Chemistry, 2009, 284, 25993-26004.	1.6	16
266	FEZ1/LZTS1 protein expression in ovarian cancer. Journal of Cellular Physiology, 2010, 222, 382-386.	2.0	16
267	POZ-, AT-hook-, and Zinc Finger-containing Protein (PATZ) Interacts with Human Oncogene B Cell Lymphoma 6 (BCL6) and Is Required for Its Negative Autoregulation. Journal of Biological Chemistry, 2012, 287, 18308-18319.	1.6	16
268	HMGA1 overexpression is associated with a particular subset of human breast carcinomas. Journal of Clinical Pathology, 2016, 69, 117-121.	1.0	16
269	Derepression of HMGA2 gene expression in retinoblastoma is associated with cell proliferation. Molecular Medicine, 2003, 9, 1.	1.9	16
270	The block of thyroglobulin synthesis, which occurs upon transformation of rat thyroid epithelial cells, is at the transcriptional level and it is associated with methylation of the 5â€² flanking region of the gene. Experimental Cell Research, 1989, 183, 277-283.	1.2	15

#	Article	IF	Citations
271	A KRAB zinc finger protein gene is the potential target of 19q13 translocation in benign thyroid tumors. , 1999, 26, 229-236.		15
272	The Eighth Fibronectin Type III Domain of Protein Tyrosine Phosphatase Receptor J Influences the Formation of Protein Complexes and Cell Localization. Journal of Biochemistry, 2009, 145, 377-385.	0.9	15
273	Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice. Endocrine-Related Cancer, 2009, 16, 483-490.	1.6	15
274	Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer. Oncotarget, 2015, 6, 19328-19335.	0.8	15
275	High mobility group A1 expression correlates with the histological grade of human glial tumors. Oncology Reports, 2004, 11, 1209.	1.2	14
276	Ligand Stimulation of a Ret Chimeric Receptor Carrying the Activating Mutation Responsible for the Multiple Endocrine Neoplasia Type 2B. Journal of Biological Chemistry, 1996, 271, 29497-29501.	1.6	13
277	Potentiation of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of thebcl-2 gene. , 1999, 81, 956-962.		13
278	IFN-Â gene expression is controlled by the architectural transcription factor HMGA1. International Immunology, 2005, 17, 297-306.	1.8	13
279	The â€œnext-generationâ€•knowledge of papillary thyroid carcinoma. Cell Cycle, 2015, 14, 2018-2021.	1.3	13
280	miR-130b-3p Upregulation Contributes to the Development of Thyroid Adenomas Targeting <i>CCDC6</i> Gene. European Thyroid Journal, 2015, 4, 213-221.	1.2	13
281	The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias. Cancer Letters, 2015, 357, 535-541.	3.2	13
282	Role of Dicer1 in thyroid cell proliferation and differentiation. Cell Cycle, 2017, 16, 2282-2289.	1.3	13
283	Characterization of inflammatory infiltrate of ulcerative dermatitis in C57BL/6NCrl-Tg(HMGA1P6)1Pg mice. Laboratory Animals, 2019, 53, 447-458.	0.5	13
284	Identification of Sumoylation Sites in CCDC6, the First Identified RET Partner Gene in Papillary Thyroid Carcinoma, Uncovers a Mode of Regulating CCDC6 Function on CREB1 Transcriptional Activity. PLoS ONE, 2012, 7, e49298.	1.1	13
285	Involvement of theHMGI(Y) gene in a microfollicular adenoma of the thyroid. Genes Chromosomes and Cancer, 1999, 24, 286-289.	1.5	12
286	Different mutations of the RET gene cause different human tumoral diseases. Biochimie, 1999, 81, 397-402.	1.3	12
287	High-mobility-group A1 (HMGA1) proteins down-regulate the expression of the recombination activating gene 2 (RAG2). Biochemical Journal, 2005, 389, 91-97.	1.7	12
288	The Mia/Cd-rap gene expression is downregulated by the high-mobility group A proteins in mouse pituitary adenomas. Endocrine-Related Cancer, 2007, 14, 875-886.	1.6	11

#	Article	IF	Citations
289	High-Mobility Group A1 Protein. Circulation Research, 2012, 110, 394-405.	2.0	11
290	Expression of CD133 in differentiated thyroid cancer of young patients. Journal of Clinical Pathology, 2015, 68, 434-440.	1.0	11
291	PATZ1 is a target of miR-29b that is induced by Ha-Ras oncogene in rat thyroid cells. Scientific Reports, 2016, 6, 25268.	1.6	11
292	High Mobility Group A proteins in esophageal carcinomas. Cell Cycle, 2016, 15, 2410-2413.	1.3	11
293	HMGA2 cooperates with either p27^{kip1} deficiency or Cdk4^{R24C} mutation in pituitary tumorigenesis. Cell Cycle, 2018, 17, 580-588.	1.3	11
294	The Metallophosphoesterase-Domain-Containing Protein 2 (MPPED2) Gene Acts as Tumor Suppressor in Breast Cancer. Cancers, 2019, 11, 797.	1.7	11
295	HMGA1-pseudogene7 transgenic mice develop B cell lymphomas. Scientific Reports, 2020, 10, 7057.	1.6	11
296	Breakpoints of 19q13 translocations of benign thyroid tumors map within a 400 kilobase region. Genes Chromosomes and Cancer, 1997, 20, 201-203.	1.5	10
297	Pivotal Role of the RB Family Proteins in in Vitro Thyroid Cell Transformation. Experimental Cell Research, 2000, 260, 257-267.	1.2	10
298	Interplay between HMGA and TP53 in cell cycle control along tumor progression. Cellular and Molecular Life Sciences, 2021, 78, 817-831.	2.4	10
299	Homeodomain-interacting Protein Kinase-2 Stabilizes p27kip1 by Its Phosphorylation at Serine 10 and Contributes to Cell Motility. Journal of Biological Chemistry, 2011, 286, 29005-29013.	1.6	9
300	Hmga1null mouse embryonic fibroblasts display downregulation of spindle assembly checkpoint gene expression associated to nuclear and karyotypic abnormalities. Cell Cycle, 2016, 15, 812-818.	1.3	9
301	Oncogene Transformation of PC Cl3 Clonal Thyroid Cell Line Induces an Autonomous Pattern of Proliferation That Correlates with a Loss of Basal and Stimulated Phosphotyrosine Phosphatase Activity. Endocrinology, 1997, 138, 3756-3763.	1.4	9
302	Ionizing Radiation Deregulates the MicroRNA Expression Profile in Differentiated Thyroid Cells. Thyroid, 2018, 28, 407-421.	2.4	8
303	A novel splice variant of the protein tyrosine phosphatasePTPRJthat encodes for a soluble protein involved in angiogenesis. Oncotarget, 2017, 8, 10091-10102.	0.8	8
304	High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. International Journal of Cancer, 2001, 91, 147-151.	2.3	7
305	Expression, purification, and characterization of rat protein tyrosine phosphatase Î· catalytic domain. Protein Expression and Purification, 2005, 41, 113-120.	0.6	7
306	Hmga1 null mice are less susceptible to chemically induced skin carcinogenesis. European Journal of Cancer, 2008, 44, 318-325.	1.3	7

#	Article	IF	Citations
307	Structural Model of the hUbA1-UbcH10 Quaternary Complex: In Silico and Experimental Analysis of the Protein-Protein Interactions between E1, E2 and Ubiquitin. PLoS ONE, 2014, 9, e112082.	1.1	7
308	Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene. Cancers, 2018, 10, 92.	1.7	7
309	Only the Substitution of Methionine 918 with a Threonine and Not with Other Residues Activates RET Transforming Potential. Endocrinology, 1997, 138, 1450-1455.	1.4	7
310	Critical role of the high mobility group A proteins in hematological malignancies. Hematological Oncology, 2022, 40, 3-11.	0.8	7
311	Multipotential hemopoietic cell lines isolated from stem cell cultures infected with friend virus complex (MuLV + F-SFFV) show presence of MuLV but not F-SFFV. Leukemia Research, 1986, 10, 187-193.	0.4	6
312	Inhibitory effects of 2-iodohexadecanal on FRTL-5 thyroid cells proliferation. Molecular and Cellular Endocrinology, 2015, 404, 123-131.	1.6	6
313	Emerging Role of USP8, HMGA, and Non-Coding RNAs in Pituitary Tumorigenesis. Cancers, 2019, 11, 1302.	1.7	6
314	Double knock-out of Hmga1 and Hipk2 genes causes perinatal death associated to respiratory distress and thyroid abnormalities in mice. Cell Death and Disease, 2019, 10, 747.	2.7	6
315	Noncoding RNAs in Thyroid-Follicular-Cell-Derived Carcinomas. Cancers, 2022, 14, 3079.	1.7	6
316	MicroRNAs: a great challenge for the diagnosis and therapy of endocrine cancers. Endocrine-Related Cancer, 2010, 17, E3-E4.	1.6	5
317	High mobility group A-interacting proteins in cancer: focus on chromobox protein homolog 7, homeodomain interacting protein kinase 2 and PATZ. Journal of Nucleic Acids Investigation, 2012, 3, 1.	0.5	5
318	CBX7 Expression in Oncocytic Thyroid Neoplastic Lesions (HÃ¼rthle Cell Adenomas and Carcinomas). European Thyroid Journal, 2014, 3, 211-6.	1.2	5
319	Identification and Synthesis of Mycalol Analogues with Improved Potency against Anaplastic Thyroid Carcinoma Cell Lines. Journal of Natural Products, 2017, 80, 1125-1133.	1.5	5
320	Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 15, 231-242.	1.7	5
321	Characterization of HMGA1P6 transgenic mouse embryonic fibroblasts. Cell Cycle, 2020, 19, 2281-2285.	1.3	5
322	Differential HMGA expression and post-translational modifications in prostatic tumor cells. International Journal of Oncology, 2005, 26, 515-20.	1.4	5
323	Transcriptional Profile of Ki-Ras-Induced Transformation of Thyroid Cells. Cancer Investigation, 2007, 25, 256-266.	0.6	4
324	New drugs in thyroid cancer. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 857-861.	1.3	4

#	Article	IF	Citations
325	Up-regulation of miR-146b and Down-regulation of miR-200b Contribute to the Cytotoxic Effect of Histone Deacetylase Inhibitors onras-Transformed Thyroid Cells. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1031-E1040.	1.8	4
326	2-iodohexadecanal Inhibits thyroid cell growth in part through the induction of let-7f microRNA. Molecular and Cellular Endocrinology, 2015, 414, 224-232.	1.6	4
327	Differential HMGA expression and post-translational modifications in prostatic tumor cells. International Journal of Oncology, 2005, 26, 515.	1.4	3
328	UbcH10 overexpression is less pronounced in older colorectal cancer patients. International Journal of Colorectal Disease, 2016, 31, 1367-1368.	1.0	3
329	The HMGA1-pseudogene7 shows oncogenic activity in vivo. Cell Cycle, 2020, 19, 2955-2959.	1.3	3
330	MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells. Cell Cycle, 2021, 20, 716-729.	1.3	3
331	HMGA1 induces EZH2 overexpression in human B-cell lymphomas. American Journal of Cancer Research, 2021, 11, 2174-2187.	1.4	2
332	The PTC oncogene is able to dedifferentiate a rat thyroid epithelial cell line in culture. Rendiconti Lincei, 1992, 3, 257-267.	1.0	1
333	Activation of the ret oncogene in human thyroid carcinomas. Rendiconti Lincei, 1993, 4, 367-375.	1.0	1
334	Corrigendum to â€œThe high mobility group A proteins contribute to thyroid cell transformation by regulating miRâ€603 and miRâ€10b expressionâ€•[Mol. Oncol. 7 (3) (Jan. 2013) 531â€“542]. Molecular Oncology, 2014, 8, 159-159.	2.1	1
335	Potentiation of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of the bcl2 gene. International Journal of Cancer, 1999, 81, 956-962.	2.3	1
336	Intracellular Signaling by the ret Tyrosine Kinase. Medical Intelligence Unit, 1996, , 37-59.	0.2	1
337	Thyroid cell transformation requires the expression of the HMGA1 proteins. , 0, .		1
338	Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. , 0, .		1
339	The role of HMGA1 protein in gastroenteropancreatic neuroendocrine tumors. Cell Cycle, 2022, 21, 1335-1346.	1.3	1
340	Glial cell line-derived nenrotrophic factor (GDNF) stimulates ret activity. Rendiconti Lincei, 1997, 8, 139-149.	1.0	0
341	Crystallization and preliminary X-ray diffraction analysis of rat protein tyrosine phosphatase Î·. Acta Crystallographica Section F: Structural Biology Communications, 2006, 62, 923-925.	0.7	0
342	POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation.. Journal of Biological Chemistry, 2014, 289, 14966.	1.6	0

#	Article	IF	Citations
343	Molecular Mechanisms of RET Activation in Human Neoplasia. , 2002, , 176-183.		0
344	The Camp-HMGA1-RBP4 System. , 2011, , 175-197.		0
345	Pituitary Adenoma: Role of HMGA Proteins. , 2013, , 161-168.		0